Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Activation of human recombinant IDE assessed as fold change in activation efficacy using ATTO 655-Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-trp as substrate at 30 uM incubated for 10 mins followed by substrate addition measured after 20 mins by fluorescence spectrophotometer analysis
Assay data:12 Tested
SummaryPubMed CitationRelated BioAssays by Target
Activation of human recombinant IDE assessed as fold change in activation efficacy using ATTO 655-Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-trp as substrate at 100 uM incubated for 10 mins followed by substrate addition and measured after 20 mins by fluorescence spectrophotometer analysis
Assay data:29 Tested
Activation of human recombinant IDE assessed as activation efficacy using ATTO 655-Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-trp as substrate at 100 uM incubated for 10 mins followed by substrate addition and measured after 20 mins by fluorescence spectrophotometer analysis relative to control
Assay data:1 Tested
Activation of human recombinant IDE using ATTO 655-Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-trp as substrate incubated for 10 mins followed by substrate addition and measured after 20 mins by fluorescence spectrophotometer analysis
Assay data:7 Active, 20 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Activation of human IDE mediated insulin hydrolysis at 100 uM pre-incubated for 1 to 10 min followed by substrate addition by HPLC analysis
Assay data:1 Active, 1 Tested
IDE Activity Assay from US Patent US9243038: "Macrocyclic insulin-degrading enzyme (IDE) inhibitors and uses thereof"
Assay data:21 Active, 15 Activity ≤ 1 µM, 29 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
In Vitro Protease Assay from US Patent US9610322: "Macrocyclic insulin-degrading enzyme (IDE) inhibitors and uses thereof"
Assay data:4 Active, 2 Activity ≤ 1 µM, 10 Tested
Inhibition of IDE (unknown origin) assessed as cleavage of Mca-RPPGFSAFK(Dnp)-OH by fluorescence assay
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Binding affinity to IDE in human HepG2 cells assessed as cell penetration at 30 uM incubated for 2 hrs by CETSA relative to control
Assay data:2 Tested
Ratio of aggregation temperature to change in aggregation temperature for binding affinity to IDE in human HepG2 cells at 30 uM incubated for 2 hrs by CETSA
Binding affinity to IDE in human HepG2 cells assessed as change in aggregation temperature at 30 uM incubated for 2 hrs by CETSA
Binding affinity to IDE in human HepG2 cells assessed as aggregation temperature at 30 uM incubated for 2 hrs by CETSA
Inhibition of human recombinant IDE harboring C110L/C171S/C178A/C257V/C414L/C573N/C590S/C789S/C812A/C819A/C904S/C966N/C974A mutant expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate at 30 uM preincubated for 10 mins followed by substrate addition and measured after 30 mins by spectrophotometric analysis relative to control
Inhibition of human recombinant IDE harboring C110L/C171S/C178A/C257V/C414L/C573N/C590S/C789S/C812A/C819A/C904S/C966N/C974A mutant expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by spectrophotometric analysis
Assay data:1 Active, 1 Activity ≤ 1 µM, 2 Tested
Inhibition of human recombinant IDE harboring C110L/C171S/C178A/C257V/C414L/C573N/C590S/C789S/C812A/C819A/C904S/C966N/C974A mutant expressed in Escherichia coli BL21 (DE3) cells using insulin as substrate preincubated for 10 mins followed by substrate addition and measured after 15 mins by fluorescence based assay
Inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using insulin as substrate preincubated for 10 mins followed by substrate addition and measured after 15 mins by fluorescence based assay
Assay data:2 Active, 2 Activity ≤ 1 µM, 2 Tested
Inhibition of wild type human IDE catalytic site using insulin as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by Luminex kit method
Reversible inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate at 1.25 uM preincubated for 30 mins followed by 100 fold compound dilution by spectrophotometric analysis
Inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate at 0.0125 uM preincubated for 10 mins followed by substrate addition and measured after 30 mins by spectrophotometric analysis relative to control
Inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate at 1.25 uM preincubated for 10 mins followed by substrate addition and measured after 30 mins by spectrophotometric analysis relative to control
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on